NUTX
Nutex Health, Inc.
NUTX offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over NUTX overall, supported by stronger fundamentals and lower modeled downside.
NUTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
NUTX's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NUTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.4x | $171 | — |
| Current | 7.2x | $171 | — |
| Cheap | 7.3x | $174 | +1.7% |
| Fair | 8.7x | $208 | +21% |
| Expensive | 11x | $255 | +49% |
Historical ranges are pointers, not guarantees.
NUTX's PE is in its cheap range at 7.2x. If earnings grow as analysts expect, today's price would be 6.4x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NUTX in the historical PE scenario, which offers more potential upside but is not a forecast.
NUTX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NUTX's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over NUTX on the outlook, with more favorable revenue expectations.
NUTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.68 | +11% |
| Q3 2026 | $23.95 | +24% |
| Q2 2026 | $26.00 | +166% |
| Q1 2026 | $13.67 | +8% |
| Q4 2025 | $10.48 | +14% |
| Q3 2025 | $19.26 | +$28.65 |
| Q2 2025 | $9.78 | +$18.95 |
| Q1 2025 | $12.66 | +$23.26 |
| Q4 2024 | $9.23 | +$21.23 |
NUTX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NUTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $217.6M | -19% |
| Q2 2026 | $210.8M | -14% |
| Q1 2026 | $216.5M | +2.2% |
| Q4 2025 | $151.7M | -41% |
| Q3 2025 | $267.8M | +240% |
| Q2 2025 | $244M | +221% |
| Q1 2025 | $211.8M | +214% |
| Q4 2024 | $257.6M | +270% |
NUTX's revenue has slid since its 2025 peak: $218M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -13 points |
| Q2 2026 | 58% | +44 points |
| Q1 2026 | 38% | -0.6 points |
| Q4 2025 | 20% | -24 points |
| Q3 2025 | 49% | +36 points |
| Q2 2025 | 14% | +6.8 points |
| Q1 2025 | 38% | +36 points |
| Q4 2024 | 44% | +82 points |
NUTX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NUTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $73.1M | -26% |
| Q2 2026 | $31.7M | +19% |
| Q1 2026 | $74.3M | +46% |
| Q4 2025 | $69M | +$69.3M |
| Q3 2025 | $99.2M | +1507% |
| Q2 2025 | $26.5M | +109% |
| Q1 2025 | $50.9M | +2096% |
| Q4 2024 | -$341.8K | +$608.8K |
NUTX has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NUTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +20.7K shares |
| 1 year | -1.9% | -136K shares |
| 3 years | +59% | +2.6M shares |
NUTX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | $19M |
| Q1 2026 | $31.7M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NUTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.0x | Net Cash |
NUTX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NUTX on leverage, with a lower net debt burden relative to earnings.
NUTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.9 | Neutral |
NUTX's weekly RSI is 48 (neutral) and its Stochastic is 43 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NUTX PE vs Healthcare Sector
| Metric | NUTX | Sector median | Relative |
|---|---|---|---|
| PE | 7.2x | 26x | 72% below |
| PE % | 13 | 29 | 16 pts below |
NUTX has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NUTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $198.8 | 14% below |
| 20 week MA | $187.7 | 8.7% below |
| 50 week MA | $153.5 | 12% above |
| 100 week MA | $123.4 | 39% above |
| 200 week MA | $86.9 | 97% above |
NUTX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 97% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NUTX on trend strength, trading above more of its moving averages.
NUTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $301.5 | $157.5 | -48% |
| 2021 | $157.5 | $619.5 | +293% |
| 2022 | $619.5 | $312.0 | -50% |
| 2023 | $312.0 | $27.0 | -91% |
| 2024 | $27.0 | $31.9 | +18% |
| 2025 | $31.9 | $176.7 | +455% |
| 2026 YTD | $176.7 | $171.4 | -3% |
NUTX's yearly returns have swung widely, from +455% in 2025 to −91% in 2023. It's down 3% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NUTX on returns for 2026, with the stronger performance.